If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
The medicine is now approved for eight indications across five different types of cancer in China.
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Subscribe To Our Newsletter & Stay Updated
